Pharmaceutical industry conferences have started banning Vectura after Philip Morris International acquired the respiratory drug manufacturer in a contentious £1 billion ($1.37 billion) takeover, reports The Times of London.
The Drug Delivery to the Lungs (DDL) conference, a leading event, has terminated Vectura’s sponsorship and the company’s representative has stepped down from its committee.
“In light of the recent acquisition of Vectura by PMI, the DDL committee [has] sadly decided that they can no longer accept support from Vectura,” the organizers said in a memo seen by The Times.